The negative funding decision for neoadjuvant pertuzumab means that roughly 1 in 6 women with HER2+ breast cancer receiving NAT will need more toxic and costly systemic therapy after surgery, rather than receiving optimal treatment pre-operatively. This evidence concerns the gene ERBB2 and breast cancer.